ASCO-GU 2026 – casdatifan starts to look competitive
Median PFS appears to back earlier response rate promise.
Another solstice for CTLA-4
Solstice Oncology acquires porustobart from Harbour Biomed.
Vir tempts Astellas
The Japanese group pays $315m to co-develop an asset Vir got from a low-cost Sanofi deal.
The non-covalent BTK space expands
Hutchmed goes pivotal with HMPL-760 in B-cell lymphoma.
Gilead buys Arcellx before it’s over the finish line
2026’s first big oncology buyout is here.
MHNCS 2026 – J&J and Bicara face off
But is Rybrevant deep enough, and does ficerafusp use the right pivotal dose?
No differentiation for Roche's degrader
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
Ideaya’s first pivotal catalyst looms
Darovasertib data are promised for the last week of March.
Sensei finds Faeth
The company buys in a PI3Kα and mTOR combo.
